Description
In the published literature, this variant has been reported in individuals with colorectal cancer and/or multiple adenomatous polyps (PMIDs: 15520370 (2004), 18033691 (2008), 28195393 (2017), 29212164 (2017)), ovarian cancer (PMID: 23047549 (2012)), breast cancer (PMIDs: 27153395 (2016), 29212164 (2017), 33471991 (2021), 35264596 (2022)), pancreatic cancer (PMID: 29945567 (2018)), and gliosarcomas (PMID: 33580181 (2021)). The variant has also been reported in unaffected individuals (PMIDs: 25637381 (2015), 33471991 (2021), 34117267 (2021)). Functional studies have conflicting reports as to whether the variant impacts MSH2 protein expression, stability, and repair (PMIDs: 1587220 (2005), 18033691 (2008), 26344056 (2015), 26344056 (2015), 26951660 (2016), 29212164 (2017), 33357406 (2021)). The frequency of this variant in the general population, 0.00073 (35/47650 chromosomes in North-Western European subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant.
# | Sample | Method | Observation |
---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
---|
1 | unknown | unknown | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |